カテゴリ： GlobalData, ドイツ, 企業調査

MediGene AG (MDG1)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：MediGene AG (MDG1) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9824
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG (MDG1) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MediGene AG, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For US$18 Million 13
Partnerships 14
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
Licensing Agreements 25
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Equity Offering 34
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Asset Transactions 41
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Acquisition 43
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG – Key Competitors 47
MediGene AG – Key Employees 48
MediGene AG – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 50
Mar 22, 2018: Medigene publishes 2017 annual report 52
Nov 09, 2017: Medigene Reports Nine Months’ Results 2017 55
Aug 03, 2017: Medigene Reports Results of First Six Months 2017 57
May 11, 2017: Medigene Reports Results Of First Quarter 2017 58
Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017 60
Corporate Communications 62
Sep 03, 2018: Medi­gene an­nounces change in ex­ec­ut­ive lead­er­ship team 62
Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 63
Aug 08, 2017: Medigene announces formation of new Scientific Advisory Board 64
May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role 65
Product News 66
08/30/2017: Medigene Presents Automated Platform For Tcr Identification At Car-Tcr Summit 66
08/28/2017: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy 67
08/25/2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 69
08/16/2017: Medigene Presents Posters on Immunotherapies at CRI-CIMT-EATI-AACR Conference 70
06/08/2017: Medigene and Academic Partners Publish a Method to Enhance Adoptive T-cell Therapies 71
04/04/2017: Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 72
03/23/2017: Medigene: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
MediGene AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Deals By Therapy Area, 2012 to YTD 2018 10
MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For US$18 Million 13
Structured Immunity and Medigene Enter into Research Agreement 14
MediGene Enters into Research Agreement with RXi Pharma 15
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16
Medigene Enters into Agreement with University of Lausanne 17
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 18
Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19
Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20
Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21
MediGene Enters Into Co-Development Agreement For EndoTAG-1 22
MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23
Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24
2A Pharma Enters into Licensing Agreement with MediGene 25
MediGene Expands Licensing Agreement with bluebird bio 26
Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29
MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30
MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31
Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32
MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33
Medigene Raises USD37.9 Million in Private Placement of Shares 34
Medigene to Raise USD18.8 Million in Private Placement of Shares 35
Medigene Raises USD22.6 Million in Private Placement of Shares 37
Medigene Raises USD52 Million in Rights Offering of Shares 38
Medigene Raises USD20.3 Million in Rights Offering of Securities 40
Fougera Pharma Acquires US Rights to Veregen from Medigene 41
SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42
Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43
Medigene Sells Minority Stake in Immunocore 44
Amgen to Acquire Catherex from Medigene 45
Medigene Acquires Trianta Immunotherapies 46
MediGene AG, Key Competitors 47
MediGene AG, Key Employees 48
MediGene AG, Subsidiaries 49

List of Figures
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[MediGene AG (MDG1)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • KYORIN Holdings Inc (4569)：製薬・医療：M&Aディール及び事業提携情報
    Summary KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries …
  • Max Life insurance Co. Ltd.：企業の戦略・SWOT・財務情報
    Max Life insurance Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Max Life insurance Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Marel hf：企業の戦略・SWOT・財務分析
    Marel hf - Strategy, SWOT and Corporate Finance Report Summary Marel hf - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Natco Pharma Ltd (NATCOPHARM)：企業の財務・戦略的SWOT分析
    Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Zetro Aerospace Corporation Sdn. Bhd.：企業の戦略・SWOT・財務情報
    Zetro Aerospace Corporation Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report Summary Zetro Aerospace Corporation Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Finnair Oyj：企業のM&A・事業提携・投資動向
    Finnair Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finnair Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Patrys Ltd (PAB)-製薬・医療分野：企業M&A・提携分析
    Summary Patrys Ltd (Patrys) is a healthcare company that provides therapeutic products. The company offers product pipeline such as PAT-SC1 used for the treatment of gastric cancer; PAT-SM6, PAT-PA1, and PAT-LM1 used to treat multiple cancers. It develops natural human antibody-based therapeutic pro …
  • Georgetown University：製薬・医療：M&Aディール及び事業提携情報
    Summary Georgetown University (GU) is an academic and research institute that offers educational services. The university provides undergraduate and graduate degree programs in the fields of law, medical, medical residencies, business administration and public policy degrees, post-doctoral positions …
  • Graham Holdings Company (GHC)：企業の財務・戦略的SWOT分析
    Graham Holdings Company (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Trident Limited：戦略・SWOT・企業財務分析
    Trident Limited - Strategy, SWOT and Corporate Finance Report Summary Trident Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Histogen Inc：医療機器：M&Aディール及び事業提携情報
    Summary Histogen Inc (Histogen) is a regenerative medicine company that develops novel therapies based on the products of cells grown under simulated embryonic conditions. The company’s products include a soluble multipotent cell conditioned media and insoluble extracellular matrix. Its products are …
  • Norsk Hydro ASA：企業の戦略・SWOT・財務分析
    Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report Summary Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • The Avascent Group：企業の戦略・SWOT・財務情報
    The Avascent Group - Strategy, SWOT and Corporate Finance Report Summary The Avascent Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hays plc (HAS)：企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Duke Energy Corporation：企業の戦略・SWOT・財務情報
    Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Broadridge Financial Solutions, Inc.：企業の戦略・SWOT・財務分析
    Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Parker Hannifin Corp (PH)：企業の財務・戦略的SWOT分析
    Parker Hannifin Corp (PH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • IDT Corp (IDT)：企業の財務・戦略的SWOT分析
    Summary IDT Corp (IDT) is a telecommunication service provider that offers mobile application development and telecommunication services. The company provides prepaid communication and payment services and international voice termination through its retail and wholesale division. It offers services …
  • Valmieras Stikla Skiedra AS：企業の戦略・SWOT・財務情報
    Valmieras Stikla Skiedra AS - Strategy, SWOT and Corporate Finance Report Summary Valmieras Stikla Skiedra AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TeleTech Holdings, Inc. (TTEC)：企業の財務・戦略的SWOT分析
    TeleTech Holdings, Inc. (TTEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆